MedTrace Logo

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

NCT05368935 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2022-10-28

No results posted yet for this study

Summary

This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with renal impairment and healthy adults.

Conditions

Interventions

DRUG

Nitazoxanide

500 mg Twice Daily for 7 days

Sponsors & Collaborators

  • Genfit

    lead INDUSTRY

Principal Investigators

  • Carol Addy, MD · Genfit

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2022-09-04
Completion
2022-09-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05368935 on ClinicalTrials.gov